Your browser doesn't support javascript.
loading
The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
McGirr, Ashleigh; Widenmaier, Robyn; Curran, Desmond; Espié, Emmanuelle; Mrkvan, Tomas; Oostvogels, Lidia; Simone, Benedetto; McElhaney, Janet E; Burnett, Heather; Haeussler, Katrin; Thano, Adriana; Wang, Xuan; Newson, Rachel S.
Afiliación
  • McGirr A; GSK Canada, 7333 Mississauga Rd N, Mississauga, ON L5N 6L4, Canada. Electronic address: ashleigh.a.mcgirr@gsk.com.
  • Widenmaier R; GSK Canada, 7333 Mississauga Rd N, Mississauga, ON L5N 6L4, Canada.
  • Curran D; GSK, 20 Avenue Fleming, Wavre 1300, Belgium.
  • Espié E; GSK, 20 Avenue Fleming, Wavre 1300, Belgium.
  • Mrkvan T; GSK, 20 Avenue Fleming, Wavre 1300, Belgium.
  • Oostvogels L; GSK, 20 Avenue Fleming, Wavre 1300, Belgium.
  • Simone B; GSK, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex UB11 1BT, United Kingdom.
  • McElhaney JE; Health Sciences North Research Institute, 41 Ramsey Lake Road, Sudbury P3E 5J1, Canada.
  • Burnett H; Evidera, 7575 Trans-Canada Hwy, Suite 404, St-Laurent, Quebec H4T 1V6, Canada.
  • Haeussler K; ICON plc, Konrad-Zuse-Platz 11, 81829 München, Germany.
  • Thano A; ICON plc, De Molen 84, Houten 3995 AX, the Netherlands.
  • Wang X; ICON plc, Klarabergsviadukten 90 Hus D, Stockholm 111 64, Sweden.
  • Newson RS; ICON plc, De Molen 84, Houten 3995 AX, the Netherlands.
Vaccine ; 37(22): 2896-2909, 2019 05 16.
Article en En | MEDLINE | ID: mdl-30982636
BACKGROUND: We estimated the relative efficacy and safety of vaccines for prevention of herpes zoster (HZ) using network meta-analysis (NMA) based on evidence from randomized controlled trials. METHODS: A systematic literature review evaluated two different HZ vaccines: adjuvanted recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL), with different formulations assessed. Detailed feasibility assessment indicated that a NMA was feasible for efficacy (incidence of HZ and postherpetic neuralgia [PHN]) and safety (serious adverse events [SAE] and reactogenicity [injection-site reactions, systemic reaction]) outcomes. Primary analyses included frequentist NMAs with fixed effects for efficacy outcomes, due to limited data availability, and both fixed and random effects for safety and reactogenicity outcomes. As age is a known effect modifier of vaccine efficacy (VE), VE analyses were stratified by age. RESULTS: RZV demonstrated significantly higher HZ efficacy than ZVL in adults ≥60 years of age (YOA) (VERZV = 0.92 (95% confidence interval [95%CI]: 0.88, 0.94), VEZVL = 0.51 (95%CI: 0.44, 0.57)) and adults ≥70 YOA (VERZV = 0.91 (95%CI: 0.87, 0.94), VEZVL = 0.37 (95%CI: 0.25, 0.48)). Similarly, RZV demonstrated significantly higher PHN efficacy than ZVL in adults ≥60 YOA (VERZV = 0.89 (95%CI: 0.70, 0.96), VEZVL = 0.66 (95%CI: 0.48, 0.78)) and adults ≥70 YOA (VERZV = 0.89 (95%CI: 0.69, 0.96), VEZVL = 0.67 (95%CI: 0.44, 0.80)). RZV was associated with significantly more injection-site and systemic reactions compared to most formulations of ZVL and placebo, however definitions and data collection procedures differed across the included studies. There were no statistically significant differences found between RZV and any formulation of ZVL or placebo for SAEs. CONCLUSION: RZV is significantly more effective in reducing HZ and PHN incidence in adults ≥60 YOA, compared with ZVL. As anticipated with an adjuvanted vaccine, RZV results in more reactogenicity following immunization. No differences in SAEs were found between RZV and ZVL.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacuna contra el Herpes Zóster Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacuna contra el Herpes Zóster Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos